We are analyzing https://link.springer.com/article/10.1007/s12272-025-01546-0.

Title:
BTK inhibitors and next-generation BTK-targeted therapeutics for B-cell malignancies | Archives of Pharmacal Research
Description:
Bruton’s tyrosine kinase (BTK) is a therapeutically validated drug target. Small-molecule inhibitors of BTK have changed the treatment paradigms of multiple B-cell malignancies and evolved over three generations to overcome clinical challenges. Four drugs are now approved by the FDA, including the first-in-class drug ibrutinib and successively approved acalabrutinib, zanubrutinib, and pirtobrutinib. The third-generation drug pirtobrutinib, which binds non-covalently to BTK, is expected to overcome resistance mutations at the covalent binding Cys481 residue of the first and second-generation drugs that covalently bind to BTK. However, some newly identified non-Cys481 resistance mutations to pirtobrutinib have shown their co-resistance to some of the covalent inhibitors, and this leaves a major unmet need that is promoting the development of next-generation BTK-targeted therapeutics. More non-covalent BTK inhibitors with differentiated binding modes are under development, and the ongoing development focus of next-generation therapeutics involves new and alternative directions to target BTK using dual-binding inhibitors and degraders of BTK, as well as its allosteric inhibitors. Recent exploration of the differentiated features of BTK inhibitors in various aspects has shown the possible link between their different features and different functional and therapeutic consequences. This review summarizes the key differentiated features of the BTK inhibitors approved by the FDA and others under development to add knowledge for their therapeutic application and future development. Long-term follow-up updates of clinical outcomes of the earlier developed drugs are also included, together with direct and indirect comparisons of efficacy and safety between the different generations of drugs. The ongoing development status of next-generation BTK-targeted therapeutics is described, with a discussion on their therapeutic potential and some limitations.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

pubmed, article, google, scholar, cas, btk, central, kinase, inhibitors, wang, tyrosine, lymphocytic, chronic, blood, brutons, ibrutinib, leukemia, phase, inhibitor, tam, bcell, malignancies, oncol, patients, httpsdoiorgblood, zanubrutinib, zhou, jurczak, lymphoma, httpsdoiorgs, brown, byrd, liu, ghia, trial, woyach, kim, acalabrutinib, versus, resistance, covalent, chen, tedeschi, med, zhang, patel, cell, development, noncovalent, bruton,

Topics {✒️}

dual-targeted protein degrader generation btk-targeted therapeutics b-cell receptor signaling month download article/chapter refractory mantle-cell lymphoma refractory b-cell nhl btk sh2-kinase interface 5-diaminopyrimidine-based affinity probe treatment-emergent adverse events protac-induced btk degradation multiple b-cell malignancies targeted protein degradation myeloid cell-mediated arthritis dual-binding inhibitors drug-resistant variants small lymphocytic lymphoma kinase-impaired btk mutations small-molecule inhibitors covalent btki-resistant cll chronic lymphocytic leukemia chronic lymphocytic leukaemia btk kinase domain differentiated binding modes full article pdf matching-adjusted indirect comparison hyung-ook kim generation therapeutics involves relapsed/refractory waldenström macroglobulinemia b-cell malignancies generation btk inhibitor b-cell malignancy refractory follicular lymphoma pharmacal research aims tyrosine kinase inhibitor orally bioavailable degrader btk inhibitors approved allosteric inhibitor asciminib related subjects accepted manuscript version battling btk mutants privacy choices/manage cookies tyrosine kinase inhibitors btk-degrader therapy allosteric kinase activation irreversible inhibitors acalabrutinib ibrutinib-resistant cll target btk kueffer le previously treated patients inhibitors targeting bruton

Schema {🗺️}

WebPage:
      mainEntity:
         headline:BTK inhibitors and next-generation BTK-targeted therapeutics for B-cell malignancies
         description:Bruton’s tyrosine kinase (BTK) is a therapeutically validated drug target. Small-molecule inhibitors of BTK have changed the treatment paradigms of multiple B-cell malignancies and evolved over three generations to overcome clinical challenges. Four drugs are now approved by the FDA, including the first-in-class drug ibrutinib and successively approved acalabrutinib, zanubrutinib, and pirtobrutinib. The third-generation drug pirtobrutinib, which binds non-covalently to BTK, is expected to overcome resistance mutations at the covalent binding Cys481 residue of the first and second-generation drugs that covalently bind to BTK. However, some newly identified non-Cys481 resistance mutations to pirtobrutinib have shown their co-resistance to some of the covalent inhibitors, and this leaves a major unmet need that is promoting the development of next-generation BTK-targeted therapeutics. More non-covalent BTK inhibitors with differentiated binding modes are under development, and the ongoing development focus of next-generation therapeutics involves new and alternative directions to target BTK using dual-binding inhibitors and degraders of BTK, as well as its allosteric inhibitors. Recent exploration of the differentiated features of BTK inhibitors in various aspects has shown the possible link between their different features and different functional and therapeutic consequences. This review summarizes the key differentiated features of the BTK inhibitors approved by the FDA and others under development to add knowledge for their therapeutic application and future development. Long-term follow-up updates of clinical outcomes of the earlier developed drugs are also included, together with direct and indirect comparisons of efficacy and safety between the different generations of drugs. The ongoing development status of next-generation BTK-targeted therapeutics is described, with a discussion on their therapeutic potential and some limitations.
         datePublished:2025-05-08T00:00:00Z
         dateModified:2025-05-08T00:00:00Z
         pageStart:426
         pageEnd:449
         sameAs:https://doi.org/10.1007/s12272-025-01546-0
         keywords:
            BTK inhibitors
            Next-generation BTK-targeted therapeutics
            Dual-binding inhibitors
            Degraders
            Allosteric inhibitors
            Pharmacy
            Pharmacology/Toxicology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12272-025-01546-0/MediaObjects/12272_2025_1546_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12272-025-01546-0/MediaObjects/12272_2025_1546_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12272-025-01546-0/MediaObjects/12272_2025_1546_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12272-025-01546-0/MediaObjects/12272_2025_1546_Fig4_HTML.png
         isPartOf:
            name:Archives of Pharmacal Research
            issn:
               1976-3786
               0253-6269
            volumeNumber:48
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Pharmaceutical Society of Korea
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Hyung-Ook Kim
               url:http://orcid.org/0000-0001-7700-1413
               affiliation:
                     name:Konyang University
                     address:
                        name:Department of Clinical Medicinal Sciences, Konyang University, Nonsan, Republic of Korea
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:BTK inhibitors and next-generation BTK-targeted therapeutics for B-cell malignancies
      description:Bruton’s tyrosine kinase (BTK) is a therapeutically validated drug target. Small-molecule inhibitors of BTK have changed the treatment paradigms of multiple B-cell malignancies and evolved over three generations to overcome clinical challenges. Four drugs are now approved by the FDA, including the first-in-class drug ibrutinib and successively approved acalabrutinib, zanubrutinib, and pirtobrutinib. The third-generation drug pirtobrutinib, which binds non-covalently to BTK, is expected to overcome resistance mutations at the covalent binding Cys481 residue of the first and second-generation drugs that covalently bind to BTK. However, some newly identified non-Cys481 resistance mutations to pirtobrutinib have shown their co-resistance to some of the covalent inhibitors, and this leaves a major unmet need that is promoting the development of next-generation BTK-targeted therapeutics. More non-covalent BTK inhibitors with differentiated binding modes are under development, and the ongoing development focus of next-generation therapeutics involves new and alternative directions to target BTK using dual-binding inhibitors and degraders of BTK, as well as its allosteric inhibitors. Recent exploration of the differentiated features of BTK inhibitors in various aspects has shown the possible link between their different features and different functional and therapeutic consequences. This review summarizes the key differentiated features of the BTK inhibitors approved by the FDA and others under development to add knowledge for their therapeutic application and future development. Long-term follow-up updates of clinical outcomes of the earlier developed drugs are also included, together with direct and indirect comparisons of efficacy and safety between the different generations of drugs. The ongoing development status of next-generation BTK-targeted therapeutics is described, with a discussion on their therapeutic potential and some limitations.
      datePublished:2025-05-08T00:00:00Z
      dateModified:2025-05-08T00:00:00Z
      pageStart:426
      pageEnd:449
      sameAs:https://doi.org/10.1007/s12272-025-01546-0
      keywords:
         BTK inhibitors
         Next-generation BTK-targeted therapeutics
         Dual-binding inhibitors
         Degraders
         Allosteric inhibitors
         Pharmacy
         Pharmacology/Toxicology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12272-025-01546-0/MediaObjects/12272_2025_1546_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12272-025-01546-0/MediaObjects/12272_2025_1546_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12272-025-01546-0/MediaObjects/12272_2025_1546_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12272-025-01546-0/MediaObjects/12272_2025_1546_Fig4_HTML.png
      isPartOf:
         name:Archives of Pharmacal Research
         issn:
            1976-3786
            0253-6269
         volumeNumber:48
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Pharmaceutical Society of Korea
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Hyung-Ook Kim
            url:http://orcid.org/0000-0001-7700-1413
            affiliation:
                  name:Konyang University
                  address:
                     name:Department of Clinical Medicinal Sciences, Konyang University, Nonsan, Republic of Korea
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Archives of Pharmacal Research
      issn:
         1976-3786
         0253-6269
      volumeNumber:48
Organization:
      name:Pharmaceutical Society of Korea
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Konyang University
      address:
         name:Department of Clinical Medicinal Sciences, Konyang University, Nonsan, Republic of Korea
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Hyung-Ook Kim
      url:http://orcid.org/0000-0001-7700-1413
      affiliation:
            name:Konyang University
            address:
               name:Department of Clinical Medicinal Sciences, Konyang University, Nonsan, Republic of Korea
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Clinical Medicinal Sciences, Konyang University, Nonsan, Republic of Korea
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(547)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.86s.

LINK . SPRINGER . COM {}